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Abstract
Background: Epithelial cell transforming sequence 2 (ECT2) is a guanine nucleotide exchange factor for Rho family GTPase,
which has been implicated in the malignant phenotype of human cancers. Little is known about the effect of a high level of
ECT2 in regulating oral cancer cell behavior. In this study, we investigated the involvement of ECT2 in oral squamous cell
carcinoma (OSCC).
Methodology/Principal Findings: We analyzed ECT2 expression in OSCC-derived cell lines and primary OSCCs compared with
matched normal tissue (n=96) by quantitative reverse transcriptase-polymerase chain reaction, Western blot, and
immunohistochemistry. We then evaluated the correlation between the ECT2 expression status in primary OSCCs and the
clinicopathological features. ECT2 expression was significantly up-regulated in OSCCs in vitro and in vivo (p,0.05). Among the
clinical variables analyzed, higher ECT2 expressiona l s ow a sa s s o c i a t e dw i t ht h eT N Ms t a g eg r a d i n g( p,0.05). When we performed
functional analyses of ECT2 in OSCC-derived cells using the shRNA system, the cellular proliferation of the ECT2 knockdown cells
decreased significantly compared with the control cells (p,0.05). Cell cycle analysis by flow cytometry showed arrest of cell cycle
progression at the G1 phase in the ECT2 knockdown cells. We also found up-regulation of the Cip/Kip family of the cyclin-
dependent kinase inhibitors, p21
cip1 and p27
kip1, and down-regulation of cyclin D1, cyclin E, and CDK4. These data suggested that
the elevated Cip/Kip family induced inhibition of the cyclin D1-CDK complex activity leading to cell cycle arrest at the G1 phase.
Conclusions/Significance: Our results proposed for the first time that ECT2 is an indicator of cellular proliferation in OSCCs
and that ECT2 might be a potential therapeutic target for the development of new treatments for OSCCs.
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Introduction
Oral squamous cell carcinoma (OSCC) is a major cause of
morbidity and mortality globally, accounting for 275,000 new
cases and more than 120,000 deaths annually [1]. Many risk
factors have been identified, including tobacco and alcohol use
[2,3,4]. However, some patients develop OSCC without risk
factors, suggesting that host susceptibility plays an important role.
Molecular changes in a number of oncogenes and tumor
suppressor genes associated with the development of OSCC could
be important clues to preventing this disease [4,5].
Microarray technology has been helpful for analyzing changes in
thousands of genes and identifying significant patterns. We previously
reported gene expression profiling of OSCC to identify cancer-
related genes [6]. Among the genes, epithelial cell transforming
sequence 2 (ECT2) was significantly up-regulated in OSCC.ECT2 is
a guanine nucleotide exchange factor (GEF) for Rho family GTPase
related to cytokinesis [7,8,9,10,11]. GEFs catalyze the exchange of
GDP for GTP, thereby activating the Rho GTPases in signal
transduction. ECT2 expression is dynamically controlled throughout
the cell cycle. Upon breakdown of the nuclear envelope during
mitosis, ECT2 is dispersed throughout the cytoplasm, then ECT2
becomes localized to the mitotic spindles during metaphase, the
cleavage furrow during telophase, and the mid-body at the end of
cytokinesis [8]. The Rho GTPases have been implicated in the
malignant phenotype of human cancers as a result of their
participation in aberrant signaling in tumor cells [12,13,14,15,16,17].
In the current study, ECT2 was frequently overexpressed in
OSCC-derived cell lines and primary OSCCs. In addition, a
shRNA experiment showed that ECT2 down-regulation resulted
in decreased cellular proliferation by cell cycle arrest of the G1
phase. Therefore, we suggested that ECT2 might be a biomarker
of proliferation and potential therapeutic target for OSCCs.
Results
Evaluation of ECT2 mRNA expression in OSCC-derived cell
lines
To investigate mRNA expression of ECT2 identified as a
cancer-related gene by our microarray analysis [6], we performed
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six OSCC-derived cell lines (HSC-2, HSC-3, HSC-4, H1, Ca9-22,
and Sa3) and human normal oral keratinocytes (HNOKs). mRNA
expression levels were normalized to GAPDH. ECT2 mRNA was
significantly up-regulated in all OSCC cell lines compared with
the HNOKs (Figure 1A, *p,0.05).
Evaluation of ECT2 protein expression in OSCC-derived
cell lines
We performed Western blot analysis to investigate ECT2
protein expression status in the OSCC-derived cell lines and the
HNOKs (Figure 1B). The molecular weight of the ECT2 was
112 kDa. A significant increase in ECT2 protein expression was
observed in all OSCC cell lines compared with the HNOKs.
Expression analysis indicated that both transcription and transla-
tion products of this molecule were highly expressed in OSCC-
derived cell lines.
Evaluation of ECT2 expression in primary OSCCs
We measured the ECT2 mRNA expression levels in primary
OSCCs and paired normal oral tissues from 96 patients. Similar to
the data from the OSCC-derived cell lines, qRT-PCR analysis
showed that ECT2 mRNA expression was up-regulated in 75
(78%) of 96 primary OSCCs compared with the matched normal
oral tissues. The relative mRNA expression levels in the normal
oral tissues and primary OSCCs ranged from 0.003 to 1.632
(median, 0.081) and 0.005 to 4.39 (median, 0.289), respectively
(Figure 2, p,0.05).
We then analyzed ECT2 protein expression by immunohisto-
chemistry (IHC). Representative IHC results for ECT2 protein in
normal oral tissue and primary OSCC are shown in Figure 3A
and B. Positive immunoreaction for ECT2 was detected in the
nucleus and cytoplasm. Strong ECT2 immunoreactions were
detected in OSCCs, whereas normal oral tissues showed negative
immunostaining. The ECT2 IHC scores of normal oral tissues and
OSCCs ranged from 8.33 to 85.33 (median, 44.00) and 55.67 to
211.33 (median, 163.33), respectively. The ECT2 IHC scores in
primary OSCCs were significantly higher than those in normal
tissues (Figure 3C, p,0.001). The correlations between the
clinicopathologic characteristics of the patients with OSCC and
the status of ECT2 protein expression using the IHC scoring
system are shown in Table 1. Among the clinical classifications,
ECT2-positive OSCCs were correlated with tumor size (p=0.043)
and TNM staging of OSCC (p=0.044) (Table 1).
Establishment of ECT2 knockdown cells
To obtain stable ECT2 knockdown transfectants, we used the
ECT2 shRNA (shECT2) plasmid and the control shRNA (Mock)
Figure 1. ECT2 exprssion in OSCC-derived cell lines. (A)
Quantification of ECT2 mRNA levels in OSCC-derived cell lines by qRT-
PCR analysis. To determine mRNA expression of ECT2 in Oral cancer, we
performed qRT-PCR analysis using six OSCC-derived cell lines (HSC-2,
HSC-3, HSC-4, H1, Ca9-22, and Sa3) and HNOKs. Significant up-
regulation of ECT2 mRNA is seen in six OSCC-derived cell lines
compared with that in the HNOKs. Data are expressed as the means
6 SEM of values from three assays (*p,0.05; Mann-Whitney U test). (B)
Western blot analysis of ECT2 protein in the OSCC-derived cell lines and
HNOKs. To investigate protein expression of ECT2 in Oral cancer, we
performed Western blot analysis using six OSCC-derived cell lines (HSC-
2, HSC-3, HSC-4, H1, Ca9-22, and Sa3) and HNOKs. ECT2 protein
expression is up-regulated in OSCC-derived cell lines compared with
HNOKs. Densitometric ECT2 protein data are normalized to a-tubulin
protein levels. The values are expressed as a percentage of the HNOKs.
doi:10.1371/journal.pone.0014082.g001
Figure 2. Comparison of ECT2 mRNA expression levels between
primary OSCCs and matched normal oral tissues. To investigate
the ECT2 mRNA expression levels in primary OSCCs and paired normal
oral tissues from 96 patients, we performed qRT-PCR analysis. The
relative mRNA expression levels in primary OSCCs and the matched oral
tissues (n=96) range from 0.005 to 4.39 (median, 0.289) and 0.003 to
1.632 (median, 0.081), respectively. ECT2 mRNA expression was up-
regulated in 75 (78%) of 96 primary OSCCs compared with the matched
normal oral tissues. Significantly higher ECT2 mRNA expression was
observed in primary OSCCs than matched normal oral tissues (P,0.05;
Mann-Whitney U test).
doi:10.1371/journal.pone.0014082.g002
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shECT2-transfected cells, we performed qRT-PCR and Western
blot analyses. Figure 4A shows that the ECT2 mRNA expression
in shECT2-transfected cells was significantly lower than in Mock-
transfected cells. ECT2 protein levels in shECT2-transfected cells
also decreased markedly compared with Mock-transfected cells
(Figure 4B). ECT2 protein expression levels were consistent with
the mRNA expression in the transfectants.
Reduced cellular growth in ECT2 knockdown cells
To investigate the antiproliferative effects in shECT2-transfect-
ed cells, cellular growth was monitored for 7 days. The shECT2-
transfected cells showed a significant decrease in cellular growth
compared with Mock-transfected cells (Figure 5).
Knockdown of ECT2 promotes cell cycle arrest
To investigate the mechanism by which ECT2 is related to cell
cycle progression, we performed FACS analysis of shECT2-
transfected cells. The percentage of the G1 phase in shECT2-
transfected cells was significantly higher than in Mock-transfected
cells (Figure 6A, p,0.05), suggesting that down-regulation of
ECT2 inhibited cellular proliferation by induction of G1 arrest.
To identify the mechanism by which ECT2 blocks G1
progression, we assessed the expression level of cyclin-dependent
kinase inhibitors (p16
INK4A, p21
cip1, p27
kip1), cyclin D1, cyclin E,
and CDK4 (Figure 6B). PCR data showed up-regulation of p21
cip1
and p27
kip1 and down-regulation of cyclin D1, cyclin E, and CDK4 in
shECT2-transfected cells.
Discussion
Our previous microarray data [6] showed significant up-
regulation of ECT2 in OSCC-derived cell lines. In the present
study, ECT2 mRNA and protein were highly expressed in vitro and
in vivo in OSCC. Regional copy number of 3q26 increases in
several cancers, such as head and neck, lung, and cervix [18,19].
This region has cancer-related genes (PRKC1 and SOX2) as well
as ECT2. Therefore, genomic unbalance would be the reason of
ECT2 overexpression in OSCC. The ECT2 protein expression
levels in primary OSCCs were correlated with the TNM stage
grading (Table 1) (p,0.05). These results suggested that ECT2 has
Figure 3. Evaluation of ECT2 protein expression in primary OSCCs. (A, B) Representative IHC results of ECT2 in normal oral tissue and
primary OSCC. (A) Normal oral tissue has no ECT2 protein expression. Original magnification, 6100. Scale bars, 50 mm. (B) ECT2-positive cases of
OSCC. Positive immunoreaction for ECT2 is detected in the nucleus and cytoplasm. Original magnification,6400. Scale bars, 10 mm. (C) State of ECT2
protein expression in nomal oral tissue and primary OSCC. To investigate protein expression of ECT2 in primary OSCCs, we carried out IHC. The ECT2
IHC scores are calculated as follows: IHC score=16(number of weak stained cells in the field)+26(number of moderately stained cells in the
field)+36(number of intensely stained cells in the field). The ECT2 IHC scores for OSCCs and normal oral tissues range from 55.67 to 211.33 (median,
163.33) and 8.33 to 85.33 (median, 44.00), respectively. The ECT2 protein expression level in OSCCs is significantly higher than that in normal oral
tissues (p,0.001; Mann-Whitney U test).
doi:10.1371/journal.pone.0014082.g003
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However, little is known about the mechanism of ECT2 in OSCC
progression. To determine whether ECT2 function is relevant to
OSCC progression, we performed the shECT2 experiment and
found that cellular proliferation decreased significantly as a result
of cell cycle arrest at the G1 phase in ECT2 knockdown cells with
up-regulation of p21
cip1 and p27
kip1 and down-regulation of cyclin
D1, cyclin E, and CDK4, indicating that ECT2 function is related
closely to OSCC progression.
GEFs, including ECT2, catalyze the exchange of GDP for
GTP, thereby activating the Rho GTPases in signal transduction
[7,8,9,10,11]. Activated Rho GTPases bind to and activate several
downstream effectors, leading to multiple biologic processes, such
as cellular size, cell cycle progression, apoptosis, survival,
morphology, cellular polarity, cellular adhesion, and membrane
trafficking [20,21]. Up-regulation of Rho GTPase activity, often
associated with tumorigenesis [22], has been detected in several
human tumors, including pancreatic cancer, breast cancer,
melanoma, lung cancer, colorectal cancer, and gastric cancer
[12,23]. On the other hand, Rho GTPases play a major role in
promoting G1-S progression through modulation of cyclin and
cyclin dependent kinase inhibitors (CDKIs) [24,25]. Yamamoto
et al. reported that when Rho GTPase was inhibited by the
Clostridium botulinum C3 toxin or a dominant negative mutant, G1-S
Table 1. Correlation between ECT2 expression and clinical classification in OSCCs.
Results of immunostaining
No. patients/%
Clinical classification Total ECT2(2) ECT2(+) p value
Age at surgery (years)
,60 28 7 25% 21 75% 0.136
60–70 27 4 15% 23 85%
70. 41 15 37% 26 63%
Gender
Male 67 19 28% 48 72% 0.669
Female 29 7 24% 22 76%
T-primary tumor size
T1 13 5 38% 8 62% 0.043*
T2 31 11 35% 20 65%
T3 24 5 21% 19 79%
T4 28 5 18% 23 82%
T1+T2 43 16 37% 27 63% 0.044*
T3+T4 53 10 19% 43 81%
N-regional lymph node metastasis
N positive 43 15 35% 28 65% 0.121
N negative 53 11 21% 42 79%
Stage
I 9 5 56% 4 44% 0.248
II 15 6 40% 9 60%
III 16 2 13% 14 87%
IV 56 13 23% 43 77%
I+II 24 11 46% 13 54% 0.017*
III+IV 72 15 21% 57 79%
Histopathologic type
Well differentiated 64 20 31% 44 69% 0.275
Moderately differentiated 28 6 21% 22 79%
Poorly differentiated 4 0 0% 4 100%
Tumor site
Gingiva 23 3 13% 20 87% 0.807
Tongue 54 19 35% 35 65%
Buccal mucosa 10 3 30% 7 70%
Oral floor 7 1 14% 6 86%
Oropharyngeal isthmus 1 0 0% 1 100%
Soft palate 1 0 0% 1 100%
*p,0.05. ECT2(+), ECT2-positive case; ECT2(2), ECT2-negative case.
doi:10.1371/journal.pone.0014082.t001
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impaired activation of GTPases is associated with constitutively
elevated levels of p21
cip1 and p27
kip1, causing cells to accumulate
in the G1 phase [27,28,29,30,31,32]. We speculated that ECT2
knockdown leads to impaired activation of Rho GTPase, and
consistent with that, we found not only up-regulation of the Cip/
Kip family (p21
cip1 and p27
kip1) but also down-regulation of cyclin
D1, cyclin E, and CDK4, leading to cell cycle arrest at the G1
phase, in ECT2 knockdown cells.
Cyclin D1, cyclin E, and CDK4 are also a critical regulator of
G1 progression and G1-S transition. Inhibition of cyclin D1, cyclin
E, and CDK4 expression blocks G1-S transition in the cell cycle
[33,34,35,36]. Cyclins D1–D3 and E families and their respective
kinase partners, CDK4/6 and CDK2, are responsible for
regulating the transition from G1 to S phase. The activities of
the cyclin-CDK complexes are modulated by two types of CDKIs,
Cip/Kip (p21
Cip1, p27
Kip1, and p57
Kip2) and the INK4 (p15
INK4B,
p16
INK4A, p18
INK4C, and p19
INK4D) families, both of which
regulate cell cycle progression [37]. Members of the Cip/Kip
family bind to cyclin-CDK complexes and inhibit their activities,
which leads to reduced phosphorylated retinoblastoma protein
and G1 cell cycle arrest.
In conclusion, our results indicated that ECT2 is overexpressed
frequently in OSCC. Furthermore, ECT2 knockdown inhibited
cellular proliferation in vitro by arresting cell cycle progression at
the G1 phase by modulating expression of cell cycle-related
molecules, which ultimately leads to inhibition of cyclin D1-CDK
complex activity. These data suggested that ECT2 plays an
important role in OSCC cell proliferation. ECT2 expression is
likely to be a biomarker of proliferation and a potential therapeutic
target for development of anticancer drugs in primary OSCCs.
Materials and Methods
Ethics Statement
All patients provided informed consent for a protocol reviewed
and approved by the institutional review board of Chiba
University. The written informed consents were obtained from
all patients.
OSCC-derived cell lines and tissue specimens
HSC-2, HSC-3, HSC-4, and Ca9-22 cell lines, derived from
human OSCCs, were purchased from the Human Science
Research Resources Bank (Osaka, Japan). H1 and Sa3 cell lines
were kindly provided by Dr. S. Fujita at Wakayama Medical
University (Wakayama, Japan). Primary cultured HNOKs were
obtained from three healthy donors [38,39]. All cells were grown
in Dulbecco’s modified Eagle medium/F-12 HAM (Sigma-Aldrich
Co, St. Louis, MO) supplemented with 10% fetal bovine serum
(Sigma) and 50 units/ml penicillin and streptomycin (Sigma).
Figure 4. Expression ECT2 in shECT2-transfected cells. To obtain stable ECT2 knockdown transfectants, we performed transfection of the ECT2
shRNA (shECT2) and the control shRNA (Mock) in OSCC cell lines (Sa3 and H1). We performed qRT-PCR and Western blot analyses to investigate ECT2
mRNA and protein expression in shECT2-transfected cells. (A) Expression of ECT2 mRNA in shECT2- and Mock-transfected Sa3 cells. (B) Western blot
analysis of ECT2 protein in shECT2- and Mock-transfected cells. The ECT2 mRNA and proteins are significantly down-regulated in shECT2-transfected
cells.
doi:10.1371/journal.pone.0014082.g004
Figure 5. Proliferation of shECT2-transfected cells. To determine
the effect of shECT2 on cellular proliferation, shECT2- and Mock-
transfected cells were seeded in 6-well plates at a density of 1610
4
viable cells per well. shECT2- and Mock-transfected cells counted on 7
consecutive days. The growth of shECT2-transfected cells is significantly
inhibited compared with the Mock-transfected cells after 7 days. The
results are expressed as the means 6 SEM of values from three assays.
The asterisks indicate significant differences between the Mock- and
shECT2-transfected cells (p,0.01; Mann-Whitney U test).
doi:10.1371/journal.pone.0014082.g005
ECT2 in Human Oral Cancer
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primary OSCC who were treated at the Chiba University
Hospital were obtained during surgical resection. The resected
tissues were divided into two parts, one of which was frozen
immediately and stored at 280uC until RNA isolation, and the
second of which was fixed in 10% buffered formaldehyde solution
for pathologic diagnosis and IHC. Histopathologic analysis of the
tissues was performed according to the World Health Organiza-
tion criteria by the Department of Pathology, Chiba University
Hospital. Clinicopathologic staging was determined by the TNM
classification of the International Union against Cancer. All
patients had OSCC that was histologically confirmed, and tumor
samples were checked to ensure that tumor tissue was present in
more than 90% of the specimen.
Preparation of cDNA
Total RNA was isolated using Trizol Reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions.
cDNA was generated from 5 mg of total RNA using Ready-To-
Go You-Prime First-Strand Beads (GE Healthcare, Buckingham-
shire, UK) and oligo (dT) primer (Sigma Genosys, Ishikari, Japan),
according to the manufacturer’s instructions.
Figure 6. shECT2 promotes G1 arrest. To investigate cell cycle progression, we analyzed Flow cytometric determination of DNA content by a
FACScalibur in the G0–G1, S, and, G2–M phases. We then determined the expression level of cyclin-dependent kinase inhibitors (p16
INK4A, p21
cip1, and
p27
kip1), cyclin D1, cyclin E, and CDK4 to identify the mechanism by which ECT2 blocks G1 progression. (A) Flow cytometric analysis was performed to
investigate cell cycle in shECT2- and Mock-transfected cells. The number of cells in the G1 has increased markedly in the ECT2 knockdown cells. (B)
qRT-PCR was performed to investigate mRNA levels of cell cycle related genes. PCR shows up-regulation of p21
cip1 and p27
kip1 and down-regulation
of cyclin D1, cyclin E, and CDK4. Data are expressed as the means 6 SEM of values from three assays (*p,0.05; Mann-Whitney U test).
doi:10.1371/journal.pone.0014082.g006
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Real-time qRT-PCR was performed to evaluate the expression
levels of target genes (ECT2, p16
INK4A, p21
cip1, p27
kip1, cyclin D1,
cyclin E, and CDK4) in OSCC-derived cells and primary OSCCs.
qRT-PCR was carried out with one method using a LightCycler
FastStart DNA Master SYBR Green 1 Kit (Roche Diagnostics
GmbH, Mannheim, Germany). The following primers were used:
ECT2, forward 59-ATTTTCATGTCGCCCGTTGT-39 and
reverse 59-CCCATGTGATGGACCAATGTC-39; p16
INK4A, for-
ward 59-CAGACATCCCCGATTGAAAGAAC-39 and reverse
59-GGTAGTGGGGGAAGGCATATATCT-39; p21
cip1, forward
59-CCCAGTTCATTGCACTTTGATTAGC-39and reverse 59-
CAGTCTAGGTGGAGAAACGGGAAC-39; p27
kip1, forward
59-CCGGCTAACTCTGAGGACAC-39and reverse 59-AGAA-
GAATCGTCGGTTGCAG-39; cyclin D1, forward 59-GCATG-
TTCGTGGCCTCTAAGA-39and reverse 59-CGGTGTAGAT-
GCACAGCTTCTC-39; cyclin E, forward 59-TTCTTGAGCAA-
CACCCTCTTCTGCAGCC-39and reverse 59-TCGCCATAT-
ACCGGTCAAAGAAATCTTGTGCC-39; CDK4, forward 59-
TGCAACACCTGTGGACATGTG-39and reverse 59-ATTTT-
GCCCAACTGGTCGG-39. Amplified products were analyzed by
3% agarose gel electrophoresis to ascertain size and purity. The
PCR reactions using the LightCycler apparatus were performed
in a final volume of 20 ml of a reaction mixture consisting of 2 ml
of FirstStart DNA Master SYBR Green I mix, 3 mM MgCl2,
and l mM of the primers, according to the manufacturer’s
instructions. The reaction mixture was loaded into glass capillary
tubes and subjected to an initial denaturation at 95uCf o r
10 min, followed by 45 rounds of amplification at 95uC( 1 0s e c )
for denaturation, 62uC (10 sec) for annealing, and 72uC( 1 0s e c )
for extension, with a temperature slope of 20uC/sec. The
transcript amounts for the target genes were estimated from the
respective standard curves and normalized to the glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) (forward 59-CA-
TCTCTGCCCCCTCTGCTGA-39and reverse 59-GGATGAC-
CTTGCCCACAGCCT-39) transcript amount determined in
corresponding samples.
Protein extraction
The cells were washed twice with cold phosphate-buffered saline
(PBS) and centrifuged briefly. The cell pellets were incubated at
4uC for 30 min in a lysis buffer (7 M urea, 2 M thiourea, 4% w/v
CHAPS, and 10 mM Tris pH 7.4) with proteinase inhibitor
cocktail (Roche). The protein concentration was measured with
BCA Protein Assay Kit (Thermo, Rockford, IL).
Western blot analysis
Protein extracts were electrophoresed on 4–12% Bis-Tris gel,
transferred to nitrocellulose membranes (Invitrogen), and blocked
for 1 h at room temperature in Blocking One (Nacalai tesque,
Kyoto, Japan). The membranes were washed three times with
0.1% Tween 20 in Tris-buffered saline and incubated with 2 mg/
ml affinity-purified rabbit anti-human ECT2 polyclonal antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4uC.
The membranes were washed again and incubated with a
1:10,000 of goat anti-rabbit IgG (H+L) HRP conjugate (Promega,
Madison, WI) as a secondary antibody for 2 h at room
temperature. Finally, the membranes were detected using Super-
Signal West Pico Chemiluminescent substrate (Thermo) and
immunoblotting was visualized by exposing the membranes to
ATTO Light-Capture II (ATTO, Tokyo, Japan). Signal intensities
were quantitated using the CS Analyzer version 3.0 software
(ATTO).
Transfection
OSCC cell lines (Sa3 and H1) were stably transfected with the
ECT2 shRNA (shECT2) or the control shRNA (Mock) (Santa
Cruz Biotechnology) construct by Lipofectamine LTX and Plus
Reagents (Invitrogen). After transfection, the cells stably shECT2
were isolated by the culture medium containing 2 mg/mL
puromycin (Invitrogen). 2–3 weeks after transfection, viable
colonies were picked up and transferred to new dishes. shECT2-
and Mock-transfected cells were used for further experiments.
IHC
IHC of 4-mm sections of paraffin-embedded specimens was
performed using rabbit anti-ECT2 polyclonal antibody (Santa Cruz
Biotechnology). Briefly, after deparaffinization and hydration, the
endogenous peroxidase activity was quenched by 30-min incuba-
tion in a mixture of 0.3% hydrogen peroxide solution in 100%
methanol, after which the sections were blocked for 2 h at room
temperature with 1.5% blocking serum (Santa Cruz Biotechnology)
in PBS before reaction with anti-ECT2 antibody (1:100 dilution) at
4uC in a moist chamber overnight. Upon incubation with the
primary antibody, the specimens were washed three times in PBS
and treated with Envision reagent (DAKO, Carpinteria, CA)
followed by color development in 3,39-diaminobenzidine tetrahy-
drochloride (DAKO). The slides then were lightly counterstained
with hematoxylin, dehydrated with ethanol, cleaned with xylene,
and mounted. Non-specific binding of an antibody to proteins other
than the antigen sometimes occurred. To avoid non-specific
binding, an immunizing peptide blocking experiment was per-
formed. As a negative control, triplicate sections were immuno-
stained without exposure to primary antibodies, which confirmed
the staining specificity. To quantify the state of ECT2 protein
expression in those components, we used IHC score systems
described previously [6,39,40,41,42,43,44,45,46,47]. Briefly, the
stained cells were determined in at least five random fields at 4006
magnification in each section. The intensity of the ECT2
immunoreaction in the cell was scored as follows: 1+, weak; 2+,
moderate; and 3+, intense. The cell number and the staining
intensity then were multiplied to produce an ECT2 IHC score.
Cases with a score exceeding 85.33 (the highest score for normal
tissue) were defined as ECT2-positive. Two independent patholo-
gists, both of whom were masked to the patients’ clinical status,
made these judgments.
Cellular proliferation
To investigate the effect of shECT2 on cellular proliferation,
shECT2- and Mock-transfected cells were seeded in 6-well plates
at a density of 1610
4 viable cells per well. At the indicated time
points, the cells were trypsinized and counted using a hemocy-
tometer in triplicate.
Cell cycle analysis
To determine cell cycle distribution, the cells were harvested,
washed with PBS, and probed with CycleTEST Plus DNA reagent
kit (Becton-Dickinson, San Jose, CA), according to the manufac-
turer’s protocol. Briefly, the cells concentrated to 5.0610
5 cells/ml
were centrifuged at 4006g for 5 min at room temperature. Then
we added 250 ml of Solution A (trypsin buffer) to the tube and
gently mixed. We allowed the trypsin to react for 10 min at room
temperature. Next, we added 200 ml of Solution B (trypsin
inhibitor and RNase in a buffer) and gently mix. We incubated
with the mixture for 10 min at room temperature. Finally, we
added 200 ml of Solution C (propidium iodide stain solution). And
we gently mixed as above and incubate for 10 min in the dark on
ECT2 in Human Oral Cancer
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by a FACScalibur (Becton-Dickinson). The fractions of the cells in
the G0–G1, S, and G2–M phases were analyzed using Flow Jo
software (Tree Star, Ashland, OR).
Statistical analysis
The statistical significance of the ECT2 expression levels was
evaluated using Fisher’s exact test or Mann-Whitney U test.
P,0.05 was considered statistically significant. The data are
expressed as the mean 6 SEM.
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